#None #Class Action #Pomerantz LLP #Immutep Limited

Investor Alert: Immutep Limited's Class Action Lawsuit

A significant investor alert has been raised regarding Immutep Limited, a company traded on NASDAQ under the symbol IMMP. Pomerantz LLP, a law firm renowned for its class action litigation, has officially announced a class action lawsuit against Immutep. The lawsuit targets individuals who may have suffered financial losses due to purported securities fraud and questionable business practices linked to the company.

Overview of the Case

The class action stems from concerns regarding the conduct of Immutep and its officers and directors. Investors are strongly encouraged to act if they acquired shares during the specified class period, particularly given the sensitive timelines associated with the case. Interested parties can reach out to Danielle Peyton at Pomerantz for further details on how to become involved.

Deadlines for Participation

Potential lead plaintiffs have a crucial deadline to meet; the court's appointment of a lead plaintiff must be requested by July 6, 2026. This allows those who purchased Immutep securities during the pertinent class period an opportunity to take a stand against the company’s alleged misconduct.

It is vital for investors who believe they qualify to gather necessary personal information, including their contact details and specifics of their share purchases when reaching out to Pomerantz. This proactive approach might be essential in securing representation and maximizing their chances of recovering losses.

What's At Stake?

The case has emerged in a context where shareholder confidence has been severely undermined by Immutep's own disclosures. On March 13, 2026, the company disclosed a pivotal press release stating that the Independent Data Monitoring Committee (IDMC) recommended terminating the TACTI-004 Phase III trial of a critical drug in development. This recommendation was based on an interim analysis which indicated futility regarding the drug’s effectiveness for its intended use in treating non-small cell lung cancer.

As a result of this announcement, the American Depositary Receipt (ADR) for Immutep endured a catastrophic decline, plummeting 82.44%—a loss of $2.27—closing at just $0.48. Such drastic declines highlight the importance of this class action lawsuit, as it raises serious questions about future company viability and potential recoveries for affected investors.

About Pomerantz LLP

Pomerantz LLP is recognized globally for its leadership in securities, antitrust, and corporate class action lawsuits. Founded by Abraham L. Pomerantz, a pioneer in the field, the firm has a longstanding tradition of protecting investor rights and has triumphed in numerous high-profile securities fraud cases. Their commitment to fighting for victims of corporate misconduct ensures that investors have a formidable ally in the event of legal disputes.

The firm operates from major cities, including New York, Chicago, and London, and remains devoted to championing the rights of its clients.

Next Steps for Investors

Investors interested in joining the class action regarding Immutep Limited should take immediate steps to contact Pomerantz LLP. Potential claimants can find additional information and access necessary documentation via the firm's website. It is critical to stay informed and act swiftly to safeguard their investment interests against potential malpractice.

For more information, contact:
Danielle Peyton
Pomerantz LLP
Email: [email protected]
Phone: 646-581-9980 ext. 7980

By advocating for what is right, investors can hold Immutep accountable while seeking justice for losses endured.